Luca Roncati1,2*
Qun Treen Huo3,4- 1Department of Surgery, Medicine, Dentistry and Morphological Sciences with Interest in Transplantation, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy
- 2Department of Laboratory Medicine and Anatomical Pathology, Institute of Pathology, University Hospital of Modena – Polyclinic, Modena, Italy
- 3Department of Chemistry, University of Central Florida, Orlando, FL, United States
- 4NanoScience Technology Center, University of Central Florida, Orlando, FL, United States
Editorial on the Research Topic
Post COVID-19: the nucleoside-modified messenger RNA (modRNA) platform
Perspective
The year 2020 marked a turning point in medicine, not only because it was the year of the Coronavirus Disease 2019 (COVID-19) pandemic outbreak, but also because in the same year, and for the first time in history, the Western drug regulatory agencies authorized the emergency use of nucleoside-modified mRNA (modRNA), embedded in lipid nanoparticles as COVID-19 vaccines, hitherto never approved for ethical reasons (1). About 30 years had passed since Malone, Felgner, and Verma of the Salk institute in San Diego succeeded in the feat of transfecting Photinus pyrais luciferase mRNA into mouse cells by exploiting lipofectin, an innovative liposome for the era (2). The researchers also noted that the translation of this mRNA could be affected by minor structural changes of the transcripts, paving the way for nucleoside modification (2). At the beginning of the 90s, liposome-incorporated mRNA encoding a viral antigen was proven to induce specific cytotoxic T lymphocytes in recipient mice (3); the same technique was then applied to mice to elicit both cellular and humoral responses against a viral or tumor antigen. The first human clinical trial using autologous dendritic cells transfected with mRNA encoding tumor antigen dates back to 2001–2002 (4); 4 years later, nucleoside modification was shown to be an effective biotechnology in avoiding the hyperactivation of the innate immune system by Toll-like receptors (5). The first human clinical trial against an infectious agent (Rabies lyssavirus) began in 2013 (6); over the next few years, clinical trials of mRNA vaccines for other viruses were started, among which Zika, Chikungunya, HIV, Influenza and Ebola (7–11). It's news this year that Karikó and Weissman have been awarded the Nobel Prize in Physiology or Medicine for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19 (12).
Article summary
In this context of great medical relevance, Frontiers in Medicine has kept faith to its mission of supporting the translation of scientific advances into new therapies and diagnostic tools that will improve patient care, and its focus has been on exploring the current and potential fields of modRNA application in an interdisciplinary approach, such as vaccinology, cancer therapy, rare diseases, genetically determined illnesses, and enzyme-replacement tools; this Research Topic has been a first step to achieve all the set goals through four new papers (two original research and two review articles).
Jonny et al. from Indonesia have reported the final analysis after 1-year follow-up regarding the safety and efficacy in phase I and phase II clinical trials of personalized vaccines made up from autologous monocyte-derived dendritic cells incubated with the spike protein of the etiological agent of COVID-19, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). A total of 28 subjects in the phase I clinical trial were randomly assigned to nine groups based on antigen and granulocyte-macrophage colony stimulating factor dosage. In the phase II clinical trial, 145 subjects were randomly grouped into three groups based on antigen dosage. During the follow-up period, no subjects in phase I experienced moderate-severe COVID-19; meanwhile, about 4% of subjects in phase II had moderate-severe COVID-19. Therefore, after 1-year follow-up, the vaccine has proven safe and effective for preventing COVID-19 (Jonny et al.).
Cacicedo et al. from Germany have tested a novel mRNA-based approach in phenylketonuric (PKU) mice showing a fast reduction in the accumulation of phenylalanine in serum, liver and brain, the organs most affected by the disease. Repeated injections of lipid nanoparticles-formulated mouse phenylalanine hydroxylase mRNA were able to rescue PKU mice from the disease phenotype for a long period of time. Therefore, a mRNA-based approach could significantly improve the quality of life in PKU patients of all ages by replacing standard-of-care treatments in the near future (Cacicedo et al.).
Ladak et al. from Canada have provided an informative update of mRNA vaccines against viruses and cancer. Highly flexible, scalable and cost-effective, mRNA therapy is a compelling vaccine platform against viruses; likewise, mRNA vaccines show similar promise against cancer as a platform capable of encoding multiple antigens for a wide range of cancers, including patient-specific ones, as a new form of personalized oncology (Ladak et al.).
Bafleh et al. from United Arab Emirates have describe key areas where mRNA-based platforms have potential clinical applications, specifically with relation to oocyte and embryo delivery of mRNA to combat infertility in humans, a pioneering approach to exploit RNA therapeutics within reproductive biology (Bafleh et al.).
Future directions
The modRNA platform represents an ongoing milestone and paradigm shift in modern pharmacology: no longer administering a protein from the outside, but providing the organism with the blueprint to synthesize the same protein from the inside. Thanks to this extraordinary platform, it is even possible to introduce heterologous modRNA into the cytoplasm of cells, bypassing transcription, inducing them to assemble proteins that they do not produce; moreover, by selecting suitable untranslated regions (UTRs) during the synthesis of a modRNA, the amount of the produced protein can be optimized (13). Important future directions of research will therefore concern vaccines based on structural peptides of emerging pathogens, antibodies against tumor antigens of the affected patient, regenerative medicine (including the regeneration of damaged cardiac muscle tissue), a broad spectrum of rare diseases caused by enzyme deficiency, high-performance systems of packaging and nano-delivery of the modRNA, non-standard nucleosides or synthetic analogs to be exploited for mRNA modifications in addition to pseudouridine or N1-methyl-pseudouridine (14, 15), and pharmacovigilance studies (16–21). This revolutionary platform, in fact, should not be exempt from continuous safety and efficacy controls as for any type of drug, always in the interest of patients' health.
Author contributions
LR: Conceptualization, Data curation, Formal analysis, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing—original draft, Writing—review & editing. QH: Project administration, Software, Supervision, Validation, Visualization, Writing—review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Roncati L, Corsi L. Nucleoside-modified messenger RNA COVID-19 vaccine platform. J Med Virol. (2021) 93:4054–7. doi: 10.1002/jmv.26924
2. Malone RW, Felgner PL, Verma IM. Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A. (1989) 86:6077–81. doi: 10.1073/pnas.86.16.6077
3. Martinon F, Krishnan S, Lenzen G, Magné R, Gomard E, Guillet JG, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur J Immunol. (1993) 23:1719–22. doi: 10.1002/eji.1830230749
4. Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. (2002) 109:409–17. doi: 10.1172/JCI14364
5. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. (2005) 23:165–75. doi: 10.1016/j.immuni.2005.06.008
6. Alberer M, Gnad-Vogt U, Hong HS, Mehr KT, Backert L, Finak G, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet. (2017) 390:1511–20. doi: 10.1016/S0140-6736(17)31665-3
7. Pardi N, Hogan MJ, Pelc RS, Muramatsu H, Andersen H, DeMaso CR, et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature. (2017) 543:248–51. doi: 10.1038/nature21428
8. Richner JM, Himansu S, Dowd KA, Butler SL, Salazar V, Fox JM, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. (2017) 168:1114–25. doi: 10.1016/j.cell.2017.02.017
9. Shaw CA, August A, Bart S, Booth PJ, Knightly C, Brasel T, et al. A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults. Vaccine. (2023) 41:3898–906. doi: 10.1016/j.vaccine.2023.04.064
10. Pardi N, Hogan MJ, Naradikian MS, Parkhouse K, Cain DW, Jones L, et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. (2018) 215:1571–88. doi: 10.1084/jem.20171450
11. Meyer M, Huang E, Yuzhakov O, Ramanathan P, Ciaramella G, Bukreyev A. Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J Infect Dis. (2018) 217:451–5. doi: 10.1093/infdis/jix592
12. The Nobel Prize. (2023). Available online at: https://www.nobelprize.org/prizes/medicine/2023/press-release/ (accessed October 2, 2023).
13. Orlandini von Niessen AG, Poleganov MA, Rechner C, Plaschke A, Kranz LM, Fesser S, et al. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3' UTRs identified by cellular library screening. Mol Ther. (2019) 27:824–36. doi: 10.1016/j.ymthe.2018.12.011
14. Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. (2015) 217:337–44. doi: 10.1016/j.jconrel.2015.08.051
15. Svitkin YV, Cheng YM, Chakraborty T, Presnyak V, John M, Sonenberg N. N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density. Nucleic Acids Res. (2017) 45:6023–36. doi: 10.1093/nar/gkx135
16. Montano D. Frequency and associations of adverse reactions of COVID-19 vaccines reported to pharmacovigilance systems in the European Union and the United States. Front Public Health. (2022) 9:756633. doi: 10.3389/fpubh.2021.756633
17. Wong HL, Hu M, Zhou CK, Lloyd PC, Amend KL, Beachler DC, et al. Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases. Lancet. (2022) 399:2191–9. doi: 10.1016/S0140-6736(22)00791-7
18. Husby A, Hansen JV, Fosbøl E, Thiesson EM, Madsen M, Thomsen RW, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. BMJ. (2021) 375:e068665. doi: 10.1136/bmj-2021-068665
19. Bernardi FF, Mascolo A, Sarno M, Capoluongo N, Trama U, Ruggiero R, et al. Thromboembolic events after COVID-19 vaccination: an Italian retrospective real-world safety study. Vaccines. (2023) 11:1575. doi: 10.3390/vaccines11101575
20. Sessa M, Kragholm K, Hviid A, Andersen M. Thromboembolic events in younger women exposed to Pfizer-BioNTech or Moderna COVID-19 vaccines. Expert Opin Drug Saf. (2021) 20:1451–3. doi: 10.1080/14740338.2021.1955101
Keywords: Coronavirus Disease 2019 (COVID-19) vaccine, messenger RNA (mRNA), nucleoside-modified mRNA (modRNA), nanoparticles, dendritic cells, personalized oncology, phenylketonuria, reproductive biology
Citation: Roncati L and Huo QT (2024) Editorial: Post COVID-19: the nucleoside-modified messenger RNA (modRNA) platform. Front. Med. 10:1324610. doi: 10.3389/fmed.2023.1324610
Received: 19 October 2023; Accepted: 14 December 2023;
Published: 04 January 2024.
Edited and reviewed by: Zoltán Jakus, Semmelweis University, Hungary
Copyright © 2024 Roncati and Huo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Luca Roncati, luca.roncati@unimore.it; roncati.luca@aou.mo.it; emailmedical@gmail.com